Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma

This Phase II study compared the safety and efficacy of IMCgp100 with investigator's choice of dacarbazine, ipilimumab, or pembrolizumab in HLA-A*0201 positive adult patients with advanced uveal melanoma. The study enrolled 378 patients who were previously untreated in the advanced setting, with no prior systemic or liver-directed chemo-, radio-, or immune-therapy allowed (prior surgical resection of liver metastases and adjuvant systemic therapy were acceptable). The study was conducted from October 16, 2017, to October 13, 2020, with results posted on September 14, 2021. The primary endpoint was overall survival, with secondary efficacy endpoints including progression-free survival, objective response rate, duration of response, and disease control rate. The abstract does not provide specific numerical results for these endpoints, safety data, or statistical comparisons between the treatment arms.

If you or someone you love is diagnosed with advanced uveal melanoma, a rare cancer that starts in the eye, you know how few good treatment options exist. This study asked a critical question for a specific group of patients: could a new, targeted drug help them live longer than the standard treatments doctors already use? The trial focused on adults with a specific genetic marker (HLA-A*0201 positive) who had not yet received any treatment for their advanced cancer. They were randomly assigned to receive either the new drug, called IMCgp100, or one of three other treatments chosen by their doctor: dacarbazine, ipilimumab, or pembrolizumab. The main goal was to see which group had better overall survival. The study also looked at other important measures, like how long the cancer stayed under control and how many patients saw their tumors shrink. The results directly compare the survival benefit of this new approach against the current standard of care, providing clear evidence for patients and doctors facing this difficult diagnosis.